Mergers: Commission partially refers acquisition of certain UDG Healthcare businesses by McKesson to UK; clears proposed merger outside UK
European Commission - Daily News
Brussels, 4 March 2016
The European Commission has today taken two decisions regarding the proposed acquisition of certain businesses from UDG Healthcare plc of Ireland by McKesson Corporation of the United States.
McKesson operates in particular in the distribution and delivery of pharmaceuticals and medical equipment. UDG will sell McKesson the following assets
(i) its pharmaceuticals wholesale business in the UK and Ireland;
(ii) TCP, a healthcare services provider in Ireland; and
(iii) MASTA, a travel healthcare business in the UK.
The Commission has partially referred the assessment of the transaction to the UK competition authority, at the latter's request. After a preliminary investigation, the Commission has found that the proposed transaction would threaten to significantly affect competition in certain markets in the UK. Those aspects will now be examined by the Competition and Markets Authority (CMA) under UK's national law. At the same time, the Commission has approved the part of the transaction affecting the European Economic Area (EEA) outside the UK. The Commission concluded that that part of the proposed transaction would raise no competition concerns, in particular because strong competitors would remain active in the market after the transaction. The transaction was examined under the normal merger review procedure. More information is available on the Commission's competition website, in the public case register under the case number M.7818.
(For more information: Ricardo Cardoso – Tel. +32 229 80100; Carolina Luna Gordo – Tel.: +32 229 68386)
Source: Europa.eu (Copyright European Commission)